Uncategorized
Support for psychedelic treatments means full steam ahead at Compass, despite stock drop
16
Jul
Jul
Though UK-based pharmaceutical company Compass Pathways reached its primary endpoint from its June 23 Phase 3 trial to use synthetic psilocybin for treatment-resistant depression (TRD), investors were seemingly underwhelmed. That same day, shares plunged 46% to a record low of $2.35 a share for the biotech firm. But Kabir Nath, CEO of Compass, defends the […]